Pipeline

Curatis identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.

The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.

 

Molecule Pre-clinical Phase I Phase II Phase III Market
C-MOH-01 treatment of medication overuse headache
C-AM-01 prevention of severe migraine with aura
C-ALS-01 ALS*

*Amyotrophic lateral sclerosis